Clinical Trial

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-08.
Trial Details
NCT Number NCT06875063
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell
Enrollment 45 participants
Start Date 2026-04-30
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-13